P
PHAT
Phathom Pharmaceuticals, Inc.
7.48
-0.27-3.48%After Hours: 7.41 -0.07 -0.94%19:30 09/18 EDT
OPEN/PREV CLOSE6.75/6.70
TODAY RANGE6.52-6.80
VOL2.09M
MARKET CAP548.51M
52 WEEK RANGE6.52-18.31
AVG VOL (3M)1.39M
% TURNOVER2.18%
TURNOVER--
P/E (TTM)-5.3181
% RANGE4.18%
EPS(TTM)-1.2749
P/E(FORWARD)-8.6369
P/B-1.5769
BVPS-4.2996
DIVIDEND--
P/S2.765
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP431.25M
SHARES OUTSTANDING80.90M
NEXT EARNINGS10/28-11/02
FREE FLOAT63.61M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·09/29 21:19
Phathom Starts Phase 3 VOQUEZNA Trial in NERD
TipRanks·09/29 12:15
Phathom Pharmaceuticals announces initiation of Phase 3 study of VOQUEZNA
TipRanks·09/21 17:56
H.C. Wainwright Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT)
Seeking Alpha·09/09 16:13
Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case
Dow Jones·09/09 15:48
Phathom Pharmaceuticals Price Target Announced at $10.00/Share by Leerink Partners
TipRanks·09/09 12:16
Leerink starts Phathom Pharmaceuticals at Market Perform on limited upside
TipRanks·09/09 10:10
Phathom Pharmaceuticals initiated with a Market Perform at Leerink
Dow Jones·08/17 14:04
Phathom Pharmaceuticals Price Target Cut to $14.00/Share From $18.00 by Barclays
Dow Jones·08/17 14:04
Phathom Pharmaceuticals Is Maintained at Overweight by Barclays
TipRanks·08/16 12:46
Phathom Pharmaceuticals price target lowered to $14 from $18 at Barclays
TipRanks·08/16 00:25
Phathom Pharmaceuticals’ Earnings Call Signals Profitable Growth
Same Industry
Name/Symbol
Change%
Price